<code id='95348E9732'></code><style id='95348E9732'></style>
    • <acronym id='95348E9732'></acronym>
      <center id='95348E9732'><center id='95348E9732'><tfoot id='95348E9732'></tfoot></center><abbr id='95348E9732'><dir id='95348E9732'><tfoot id='95348E9732'></tfoot><noframes id='95348E9732'>

    • <optgroup id='95348E9732'><strike id='95348E9732'><sup id='95348E9732'></sup></strike><code id='95348E9732'></code></optgroup>
        1. <b id='95348E9732'><label id='95348E9732'><select id='95348E9732'><dt id='95348E9732'><span id='95348E9732'></span></dt></select></label></b><u id='95348E9732'></u>
          <i id='95348E9732'><strike id='95348E9732'><tt id='95348E9732'><pre id='95348E9732'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          Wikipedia